Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Prizes
Activities
Press/Media
Student theses
Search by expertise, name or affiliation
Targeting IGF-1 signaling pathways in gynecologic malignancies
Ilan Bruchim,
Haim Werner
*
*
Corresponding author for this work
Human Molecular Genetics Biochemistry
Tel Aviv University
Meir Hospital Sapir Medical Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
57
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting IGF-1 signaling pathways in gynecologic malignancies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Growth Factors
100%
Insulin-like
100%
Signaling Pathway
100%
Gynecologic Malignancies
100%
Gynecological Cancer
23%
Malignancy
15%
Ovarian Cancer
15%
Targeted Therapy
15%
Targeted Agents
7%
A1 Receptor
7%
Etiology
7%
Effective Treatment
7%
Expression Level
7%
Breast
7%
Transformed Cells
7%
In Cancer
7%
Expert Opinion
7%
Area Cover
7%
Tumor Progression
7%
In Vitro Study
7%
Cancer Therapy
7%
Cell Survival
7%
Treatment Modalities
7%
Anti-apoptotic
7%
Colon
7%
Apoptotic Cells
7%
Endometrial Cancer
7%
Cervical Cancer
7%
Transforming Activity
7%
Targeted Cancer Therapy
7%
Prostate
7%
Multiple Approaches
7%
Factor System
7%
Tumor Initiation
7%
Tumor Expression
7%
Circulating Levels
7%
Growth Factor Pathway
7%
Small Molecule Tyrosine Kinase Inhibitors
7%
Epithelial Neoplasm
7%
Pre-clinical and Clinical Trials
7%
Medicine and Dentistry
Signal Transduction
100%
Cancer
100%
Somatomedin C
100%
Somatomedin
100%
Female Genital Tract Cancer
27%
Malignant Neoplasm
18%
Neoplasm
18%
Ovarian Cancer
18%
In Vitro
9%
Clinical Study
9%
Tyrosine-Kinase Inhibitor
9%
Tumor Progression
9%
Clinical Trial
9%
Cancer Therapy
9%
Cell Survival
9%
Transformed Cell
9%
Colon
9%
Endometrial Cancer
9%
Cervical Cancer
9%
Targeted Therapy
9%
Somatomedin C Receptor
9%
Antiapoptotic
9%
Tumor Initiation
9%
Molecularly Targeted Therapy
9%
Uterine Cancer
9%
Pharmacology, Toxicology and Pharmaceutical Science
Somatomedin C
100%
Somatomedin
100%
Malignant Neoplasm
36%
Neoplasm
27%
Female Genital Tract Cancer
27%
Ovary Cancer
18%
Clinical Trial
9%
Clinical Study
9%
Antiapoptotic
9%
Endometrium Cancer
9%
Protein Tyrosine Kinase Inhibitor
9%
Preclinical Study
9%
Somatomedin C Receptor
9%
Uterine Cervix Cancer
9%
Uterus Cancer
9%